RxDoctor Payments DataLook up a doctor →

Manuel Sainz de la Pena, MD

Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1194775817

Payments from drug & device makers

$246,859in general payments, 2019–2025

Across 1,146 payments — averaging $215.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$198K
  • Bayer$21K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
  • Sanofi-aventis U.S. LLC$4K
  • Abbott$3K
  • Amgen$1K
  • plus $12K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk325$198,143
Bayer55$21,253
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$6,500
Sanofi-aventis U.S. LLC57$3,996
Abbott36$3,291
Amgen(2 entities)57$1,442
Corcept Therapeutics70$1,279
Lilly USA, LLC59$971
Boehringer Ingelheim48$870
Amarin Pharma, Inc.71$749
AstraZeneca(2 entities)33$692
Dexcom, Inc.28$607
Recordati_rare_diseases_inc.21$502
Mannkind Corporation22$496
Senseonics, Incorporated2$414
AbbVie23$383
Esperion Therapeutics, Inc.8$364
Tandem Diabetes Care, Inc.15$331
Renalytix AI, Inc.8$294
Xeris Pharmaceuticals, Inc.15$289
Radius Health, Inc.9$269
Amneal Pharmaceuticals LLC13$236
Amryt Pharma Holdings Ltd5$220
Antares Pharma, Inc.9$213
Nevro Corp.10$209
Insulet Corporation9$195
Kyowa Kirin, Inc.4$190
IBSA Pharma Inc.9$170
Johnson & Johnson12$164
Shire North American Group Inc7$158
Medtronic(2 entities)8$150
Ascendis Pharma Endocrinology Inc6$143
Cequr Corporation1$122
BETA Bionics, Inc.4$101
Companion Medical, Inc.5$100
United Therapeutics Corporation1$100
Merck4$95
EUSA Pharma (US) LLC4$89
Madrigal Pharmaceuticals3$82
Valeritas, Inc.3$76
Sequel Med Tech, LLC3$72
Avvisto Therapeutics, LLC4$70
Ascensia Diabetes Care US Inc.1$68
Lifescan, Inc.3$63
Rhythm Pharmaceuticals, Inc.2$63
Pfizer3$53
Novartis2$51
OPKO Pharmaceuticals, LLC2$50
Averitas Pharma Inc.2$47
Zealand Pharma US, Inc.2$44
Soleno Therapeutics, Inc.2$41
Neurocrine Biosciences, Inc.1$35
Acerus Pharmaceuticals Corporation1$32
Takeda Pharmaceuticals U.S.A., Inc.2$30
Verity Pharmaceuticals Inc.1$27
Astellas Pharma US Inc1$25
Ipsen Biopharmaceuticals, Inc1$23
Hikma Pharmaceuticals USA1$22
RGH Enterprises LLC1$21
Ultragenyx Pharmaceutical Inc.1$19

How this compares

$246,859 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$166,706
Medicare patients
535
Services billed
2,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Tampa

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →